Want to see EVH full AI Analyst Report?
EVH Stock Chart & Stats
$4.22
$0.00(0.00%)
At close: 4:00 PM EDT
$4.22
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.10 - $10.08
Previous CloseN/A
Volume827.94K
Average Volume (3M)2.67M
Market Cap
$446.58M
Enterprise Value$1.44K
Total Cash (Recent Filing)$115.70M
Total Debt (Recent Filing)$3.97M
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Nov 04, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.49
Shares Outstanding113,059,330
10 Day Avg. Volume3,303,213
30 Day Avg. Volume2,668,208
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.10
Price to Sales (P/S)0.24
P/FCF Ratio96.07
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.86Price Target Upside38.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)0.18
Revenue Forecast (FY)$2.50B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA 31% sequential Q2 revenue surge and TTM re-acceleration (~11%) signal durable demand and stronger contract scale. Large launches and Performance Suite wins expand covered lives and recurring fee volume, improving multi‑period revenue visibility and supporting sustained top‑line growth.
Cash GenerationPositive operating and free cash flow after prior negative periods indicates improving cash conversion. Sustained FCF supports reinvestment in software, incremental product rollouts, and targeted debt reduction without relying solely on profit improvement, strengthening medium‑term financial flexibility.
Balance Sheet DeleveragingA much lower debt-to-equity profile materially improves solvency and optionality versus prior years. With equity sizeable and leverage reduced, management has more room to refinance maturities, fund strategic launches and absorb cyclical pressures while executing a multi‑quarter deleveraging plan.
Bears Say
Sustained Net LossesA persistent, large net loss and negative operating margins undermine returns on capital and limit retained earnings available for growth. Even with improving revenue and cash, continued structural unprofitability risks long‑term ROI, investor confidence and the ability to sustainably scale margins.
MER & Margin CompressionRising medical expense ratio and a shift toward large, lower‑margin capitated contracts create structural pressure on consolidated margins. Even as revenue scales, the mix‑driven margin compression can restrain long‑term profitability unless per‑contract care margins materially improve.
High Net Leverage & Refinancing RiskSubstantial net debt and near‑term maturities concentrate refinancing and interest‑coverage risk, especially with modest operating cash flow guidance. Elevated leverage can limit strategic investments and force prioritization of liability management over product or commercial expansion until capital structure is repaired.
Evolent Health News
EVH FAQ
What was Evolent Health Inc.’s price range in the past 12 months?
Evolent Health Inc. lowest stock price was $2.10 and its highest was $10.08 in the past 12 months.
What is Evolent Health Inc.’s market cap?
Evolent Health Inc.’s market cap is $446.58M.
When is Evolent Health Inc.’s upcoming earnings report date?
Evolent Health Inc.’s upcoming earnings report date is Nov 04, 2026 which is in 86 days.
How were Evolent Health Inc.’s earnings last quarter?
Evolent Health Inc. released its earnings results on Aug 06, 2026. The company reported $0.02 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.03.
Is Evolent Health Inc. overvalued?
According to Wall Street analysts Evolent Health Inc.’s price is currently Undervalued.
Does Evolent Health Inc. pay dividends?
Evolent Health Inc. does not currently pay dividends.
What is Evolent Health Inc.’s EPS estimate?
Evolent Health Inc.’s EPS estimate is 0.06.
How many shares outstanding does Evolent Health Inc. have?
Evolent Health Inc. has 113,059,330 shares outstanding.
What happened to Evolent Health Inc.’s price movement after its last earnings report?
Evolent Health Inc. reported an EPS of $0.02 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 16.558%.
Which hedge fund is a major shareholder of Evolent Health Inc.?
Currently, no hedge funds are holding shares in EVH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evolent Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.86 (38.89% Upside)
$5.86 (38.89% Upside)
Blogger Sentiment
Bullish
EVH Sentiment 75%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 86.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 88%
Bearish news 13%
Bearish news 13%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-54.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-19.89%
Trailing 12-Months
Company Description
Evolent Health Inc.
Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.
EVH Company Deck
EVH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a balanced mix of strong operational execution and growth momentum (notably 31% QoQ revenue growth, a 50% jump in Performance Suite revenue, raised 2026 revenue guidance, a large oncology deal, and meaningful AI progress) alongside notable near-term challenges (elevated MER, membership headwinds from Medicaid/exchange, timing variability in EBITDA recognition, and elevated net leverage). Management expressed confidence in 2027 growth (>25% revenue) and margin recovery driven by AI, Performance Suite maturation and cost actions, but acknowledged material macro- and client-specific risks that temper near-term financial clarity.View all EVH earnings summariesEVH Stock 12 Month Forecast
Average Price Target
$5.86
▲(38.89% Upside)
Technical Analysis
Ownership Overview
2.84% Insiders
13.41% Mutual Funds
2.52% Other Institutional Investors
68.38% Public Companies and
Individual Investors